Key result
The familial defective apolipoprotein B-100 Arg3500Gln mutation had a prevalence of 1.83% (3/164) in hypercholesterolemic children and 3.2% in families with monogenic pure hypercholesterolemia.
Why the study?
What is the prevalence of the Apolipoprotein B Arg3500Gln mutation in French children with hypercholesterolemia?
Cross-Sectional (n=190)
Yes
What is the prevalence of the Apolipoprotein B Arg3500Gln mutation in French children with hypercholesterolemia?
The familial defective apolipoprotein B-100 mutation has a prevalence of 1.83% in French children with hypercholesterolemia, supporting genetic screening in this population to prevent premature cardiovascular events.
Low prevalence does not support routine screening; leaves open the mutation's contribution to monogenic hypercholesterolemia in French children.
BACKGROUND: Familial defective apolipoprotein B-100, a dominantly inherited form of hypercholesterolemia caused by a single Arg3500Gln mutation, is silent in childhood but may confer a high risk of cardiovascular disease in adulthood. The objective was to determine the prevalence of familial defective apolipoprotein B-100 in hypercholesterolemic French children and to provide a basis for targeting screening efforts in this population. METHODS: One hundred ninety children attending 13 pediatric clinics distributed throughout France were included based on the presence of type IIa hypercholesterolemia with a plasma low-density lipoprotein-cholesterol level of more than 130 mg/dL. The Arg3500Gln mutation was detected in dried blood spots using a polymerase chain reaction assay combined with enzymatic restriction. RESULTS: Three hyperlipidemia phenotypes were found: monogenic dominant pure hypercholesterolemia (n = 117), polygenic hypercholesterolemia (n = 43), and combined hyperlipidemia (n = 11). Three unrelated children were heterozygous for the Arg3500Gln mutation; all three had monogenic dominant pure hypercholesterolemia (3/94 families; 3.2%), yielding a prevalence of 1.83% (3/164) in hypercholesterolemic children, which is similar to prevalences reported in European adults. CONCLUSIONS: The familial defective apolipoprotein B-100 mutation was common (1/31) in children with a phenotype of familial hypercholesterolemia, supporting screening in this population with the goal of preventing premature cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Viola et al. (2001) conducted a cross-sectional in Hypercholesterolemia (n=190). Apolipoprotein B Arg3500Gln mutation was evaluated on Prevalence of the Arg3500Gln mutation. The familial defective apolipoprotein B-100 Arg3500Gln mutation had a prevalence of 1.83% (3/164) in hypercholesterolemic children and 3.2% in families with monogenic pure hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: